Kappac Pharma Peer Comparison

BSE: 506938

₹112.85

₹-5.90 (-4.97%)

As on 06-Jan-2015IST

Market cap

₹341 Cr

Revenue (TTM)

₹0 Cr

P/E Ratio

--

P/B Ratio

9

Div. Yield

0 %

Edit

	Kappac Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Market cap (₹ Cr)	341	32,104	29,892	29,103	26,871
Revenue (₹ Cr)	--	3,564	1,936	9,205	1,462
Net Profit (₹ Cr)	-2.20	414.00	288.22	-371.81	387.35
Net Margin (%)	101.15	11.23	14.79	-3.93	26.01
RoE (%)	-6.25	8.38	29.77	-3.85	25.18
Price to Earnings	--	78.49	103.71	--	69.57
Price-To-Book	8.97	6.38	22.27	3.64	15.55

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement (₹ Cr)

	Kappac Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Operating Revenue	--	4,830.36	41.58	--	76.11
Total Income	0.00	4,914.64	41.73	--	76.68
Total Expenditure	0.08	3,850.53	30.00	--	69.99
EBITDA	-0.08	979.83	11.59	--	6.12
Depreciation	--	139.92	3.35	--	0.80
EBIT	-0.08	839.91	8.24	--	5.32
Interest	0.00	83.35	2.34	--	1.58
Other Income	--	84.28	0.14	--	0.56
Exceptional Items	--	49.83	--	--	--
Profit before Tax	-0.08	890.67	6.04	--	4.31
Provision for Tax	--	47.88	1.54	--	1.44
Profit after Tax	-0.08	842.79	4.50	--	2.86

Liabilities (₹ Cr)

	Kappac Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Shareholder's Funds	38.11	3,581.47	44.83	--	10.77
Minority Interest	--	136.17	--	--	--
Non-Current Liabilities	0.00	1,161.18	10.36	--	1.29
Current Liabilities	0.50	1,743.20	21.34	--	26.33
Total Liabilities	38.61	6,622.02	76.53	--	38.71

Assets (₹ Cr)

	Kappac Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Non-Current Assets	8.31	3,266.10	51.75	--	7.38
Current Assets	30.30	3,355.92	24.78	--	31.01
Total Assets	38.61	6,622.02	76.53	--	38.71
Total Debt*	0.49	1,906.08	21.09	--	12.17
Net Current Assets	29.80	1,612.72	3.44	--	4.68
Contingent Liabilities	--	267.40	4.70	--	--

Cashflow (₹ Cr)

	Kappac Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Cash From Operating Activities	4.19	1,476.29	6.29	--	-0.21
Cash Flow from Investing Activities	-5.42	-851.62	-5.46	--	-2.00
Cash from Financing Activities	-4.24	-601.32	-0.58	--	2.17
Net Cash Inflow / Outflow	-0.04	23.35	0.25	--	-0.04

Ratios

Profitability Ratios

	Kappac Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
ROCE (%)	-0.27	18.98	13.38	--	29.97
ROE (%)	-0.27	30.04	19.08	--	30.26
ROA (%)	-0.26	13.36	6.16	--	8.85
EBIT Margin (%)	--	22.03	28.21	--	8.78
Net Margin (%)	--	17.15	10.78	--	3.74
Cash Profit Margin (%)	--	20.32	18.86	--	4.81

Growth Ratios

	Kappac Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Revenue Growth (%)	--	-13.89	12.11	--	37.10
EBIT Growth (%)	-0.28	-49.66	21.82	--	30.95
Net Profit Growth (%)	0.08	-46.64	58.36	--	39.55
EPS Growth (%)	21.43	-56.04	58.36	--	39.55
Book Value Growth (%)	59.47	36.37	21.09	--	32.03

Valuation Ratios

	Kappac Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Price / Earnings	0.00	6.59	0.00	--	0.00
Price / Book Value	54.69	1.55	0.00	--	0.00
Dividend Yield (%)	0.00	2.19	--	--	--
EV/EBITDA	0.00	5.73	3.52	--	2.02
Market Cap (₹ Cr)	--	5,016.58	0.00	--	0.00

Solvency Ratios

	Kappac Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debt to Equity	0.01	0.54	0.47	--	1.13
Short term debt to equity ratio	0.01	0.06	0.23	--	0.84
Current Ratio	60.78	1.93	1.16	--	1.18
Quick Ratio	60.78	1.36	1.11	--	0.75
Interest Coverage	-3,866.11	11.69	3.58	--	3.73

Operating Efficiency Ratios

	Kappac Pharma	Wockhardt	Rubicon Research	Piramal Pharma	Acutaas Chemicals
Debtors to sales (%)	--	9.96	33.85	--	17.81
Asset Turnover	0.00	0.77	0.57	--	2.35
Receivable days	--	54.33	106.93	--	58.46
Inventory Days	--	77.43	10.49	--	41.85
Payable days	--	120.43	213.33	--	91.25
Cash Conversion Cycle	--	11.32	-95.91	--	9.06

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly